Do you know your LDL? It’s the bad cholesterol and the American Heart Association says we should keep it under 100 to avoid heart attacks and strokes, but for some people no matter what they do their LDL numbers skyrocket. Now, a drug that’s just hit the market could help bring it back down to earth.
Wenter Blair is a shutterbug.
“Heaven forbid something does happen to me, my babies have a really good idea of who I am through my photography,” Wenter Blair, HoFH patient, said.
She suffers from an inherited condition called HoFH. Her body retains bad cholesterol.
“Every night I go to bed fearful that it might be my last night,” Blair said.
Wenter’s LDL levels are usually around 350. She's already had three heart attacks.
“I know I don’t have it under control and it scares the living crud out of me,” Blair said.
The FDA recently approved a new drug called Kynamro.
“A technology that’s been in development for 30 years and this is the first real breakthrough in that technology,” said Paula Soteropoulos, general manager for Genzyme.
Developed in part by Genzyme, Soteropoulos says the once a week injection resulted in an average 25 percent drop in LDL levels.
“This is getting them to levels they have never seen before,” Soteropoulos said.
Wenter says this and other drugs in the works are giving her a better picture of what her future could be.
“I want to live a really long time and without them I won’t see the longevity that I so crave,” Blair said.
Kynamro is not a stand-alone drug. It’s designed to be added to their treatment regimen. The most serious risk of Kynamro is liver toxicity.